{"id":"W4416391865","doi":"10.1016/j.annonc.2025.09.095","title":"LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"David Geffen School of Medicine, University of California, Los Angeles; Ono Pharmaceutical; Yonsei University College of Medicine; Seoul National University; European Society for Medical Oncology; College of Medicine, Seoul National University; Genentech; Seoul National University Hospital; KU Leuven; Weill Cornell Medical College; National Institute for Health and Care Research; Pfizer; Yonsei University; Memorial Sloan-Kettering Cancer Center; Cancer Research Institute; AstraZeneca; American Society of Clinical Oncology; Université de Montréal; University of Victoria; Daiichi Sankyo Europe; Gilead Sciences; Hospital de Câncer de Barretos; Amgen; Ipsen; BeiGene","keywords":"Nivolumab; Regorafenib; Refractory (planetary science); Chemotherapy; Gastroesophageal Junction; Phases of clinical research; Ramucirumab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001452563,0.0005373525,0.003395641,0.001296567,0.00005492923,0.00002194399,0.0005233234,0.0002345895,0.0004523057],"category_scores_gemma":[0.001449814,0.0004106622,0.0004697791,0.001949671,0.0005424293,0.0001791906,0.0001877586,0.0005235827,0.000004638369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000497899,"about_ca_system_score_gemma":0.001690352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005362158,"about_ca_topic_score_gemma":0.004032411,"domain_scores_codex":[0.9955941,0.0007025944,0.001842384,0.0007102858,0.0004023748,0.0007481893],"domain_scores_gemma":[0.9968483,0.0007732663,0.0009719359,0.0006615982,0.000466049,0.0002788276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5473762,0.009553167,0.1959811,0.001168276,0.004392886,0.0007701297,0.005365074,0.00009796856,0.001296272,0.0001660873,0.06105587,0.172777],"study_design_scores_gemma":[0.9090538,0.02397165,0.04340601,0.001349036,0.00192701,0.00002861598,0.002355629,0.001358846,0.003746764,0.0001827808,0.01212878,0.0004910987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845431,0.001745179,0.0001787482,0.006914107,0.0004063945,0.004509468,0.00002617448,0.00008695908,0.00158984],"genre_scores_gemma":[0.9879016,0.002388016,0.0004000705,0.003645034,0.0001482713,0.0006419209,0.00004301502,0.0000484268,0.004783653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3616776,"threshold_uncertainty_score":0.9998345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06575530322274843,"score_gpt":0.4238620774123215,"score_spread":0.358106774189573,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}